Barriers and facilitators to viral hepatitis testing in Uzbekistan: scoping qualitative study among key stakeholders, healthcare workers, and the general population
- PMID: 38831285
- PMCID: PMC11145832
- DOI: 10.1186/s12889-024-18953-5
Barriers and facilitators to viral hepatitis testing in Uzbekistan: scoping qualitative study among key stakeholders, healthcare workers, and the general population
Abstract
Introduction: In the World Health Organization European Region, an estimated 14 million people live with a chronic hepatitis B virus infection (HBV), and 12 million are affected by a hepatitis C virus infection (HCV). Uzbekistan bears a major burden of HBV and has one of the highest HCV prevalence in the region. Following a presidential decree in May 2022, significant funds were allocated to the viral hepatitis (VH) elimination program in Uzbekistan. The program expands VH testing to reach 500,000 people annually during 2022-2025 as part of the VH elimination strategy that includes the provision of free testing and affordable treatment. Exploring the existing barriers and facilitators to VH testing is pivotal for informing these interventions.
Methods: This study uses a cross-sectional qualitative design to identify and explore the barriers and facilitators to VH testing among the general population in Uzbekistan. We collected data during October-November 2022 through semi-structured interviews with 12 key informants (KIs) and 7 focus group discussions with two target populations: the general population and healthcare workers (HCW) in Tashkent, Uzbekistan.
Results: Following the capability-opportunity-motivation-behavior model (COM-B model) as a framework for the analysis, we identified major capability barriers to VH testing primarily linked to low health literacy and limited knowledge about VH types, symptoms, transmission, testing and treatment. Physical opportunity barriers included the time and financial costs associated with testing, diagnostics, and treatment. Sociocultural opportunity barriers involved anticipated negative reactions and stigmatization, particularly affecting women. Motivational barriers included a reluctance to be tested when asymptomatic and a general fear of receiving positive test results. The involvement of healthcare workers in promoting VH awareness and motivating the general population emerged as a facilitator.
Conclusions: A multi-pronged approach is recommended to achieve VH testing goals among the general population, focusing on raising awareness and health literacy and creating an enabling environment that ensures easy accessibility and minimizing VH testing-associated costs.
Keywords: Barriers and facilitators; Behavior change; Central Asia; Elimination; Hepatitis testing.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Similar articles
-
Progress Toward Hepatitis B and Hepatitis C Elimination Using a Catalytic Funding Model - Tashkent, Uzbekistan, December 6, 2019-March 15, 2020.MMWR Morb Mortal Wkly Rep. 2020 Aug 28;69(34):1161-1165. doi: 10.15585/mmwr.mm6934a3. MMWR Morb Mortal Wkly Rep. 2020. PMID: 32853186 Free PMC article.
-
Informing the design of a national screening and treatment programme for chronic viral hepatitis in primary care: qualitative study of at-risk immigrant communities and healthcare professionals.BMC Health Serv Res. 2015 Mar 13;15:97. doi: 10.1186/s12913-015-0746-y. BMC Health Serv Res. 2015. PMID: 25890125 Free PMC article.
-
Barriers and facilitators for implementation of HPV-based cervical cancer screening in Tanzania: a qualitative study among healthcare providers, stakeholders, and Tanzanian women.Glob Health Action. 2025 Dec;18(1):2491852. doi: 10.1080/16549716.2025.2491852. Epub 2025 Apr 24. Glob Health Action. 2025. PMID: 40270234 Free PMC article.
-
Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: Where are we now and barriers to meeting World Health Organization targets by 2030.J Gastroenterol Hepatol. 2019 Jan;34(1):40-48. doi: 10.1111/jgh.14457. Epub 2018 Sep 27. J Gastroenterol Hepatol. 2019. PMID: 30151932 Review.
-
The epidemiology of Hepatitis B, C and D in Germany: A scoping review.PLoS One. 2020 Mar 9;15(3):e0229166. doi: 10.1371/journal.pone.0229166. eCollection 2020. PLoS One. 2020. PMID: 32150561 Free PMC article.
References
-
- WHO, Hepatitis, C in the WHO European Region - factsheet July. 2022. World Health Organization. Published 2023. Accessed July 24, 2023. https://www.who.int/europe/publications/m/item/hepatitis-c-in-the-who-eu...
-
- WHO, Hepatitis, B in the WHO European Region - factsheet July. 2022. World Health Organization. Published 2023. Accessed July 24, 2023. https://www.who.int/europe/publications/m/item/hepatitis-b-in-the-who-eu...
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources